Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $19.60 million. The enterprise value is $19.92 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 11.53 million shares outstanding. The number of shares has increased by 113.52% in one year.
| Current Share Class | 11.53M |
| Shares Outstanding | 11.53M |
| Shares Change (YoY) | +113.52% |
| Shares Change (QoQ) | +75.26% |
| Owned by Insiders (%) | 18.05% |
| Owned by Institutions (%) | 0.65% |
| Float | 8.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.25 |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 38.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.12 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -689.73 |
Financial Efficiency
Return on equity (ROE) is -115.89% and return on invested capital (ROIC) is -60.45%.
| Return on Equity (ROE) | -115.89% |
| Return on Assets (ROA) | -53.55% |
| Return on Invested Capital (ROIC) | -60.45% |
| Return on Capital Employed (ROCE) | -46.66% |
| Revenue Per Employee | $170,361 |
| Profits Per Employee | -$4.02M |
| Employee Count | 3 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.66% in the last 52 weeks. The beta is 2.76, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.76 |
| 52-Week Price Change | -65.66% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 41.83 |
| Average Volume (20 Days) | 177,341 |
Short Selling Information
The latest short interest is 116,814, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 116,814 |
| Short Previous Month | 249,327 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 0.56 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $511,084 and -$12.05 million in losses. Loss per share was -$4.41.
| Revenue | 511,084 |
| Gross Profit | 294,630 |
| Operating Income | -9.45M |
| Pretax Income | -9.02M |
| Net Income | -12.05M |
| EBITDA | -8.31M |
| EBIT | -9.45M |
| Loss Per Share | -$4.41 |
Full Income StatementBalance Sheet
The company has $76,496 in cash and $47,713 in debt, giving a net cash position of $28,783 or $0.00 per share.
| Cash & Cash Equivalents | 76,496 |
| Total Debt | 47,713 |
| Net Cash | 28,783 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 20.25M |
| Book Value Per Share | 2.83 |
| Working Capital | -1.33M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.15M |
| FCF Per Share | -$0.53 |
Full Cash Flow StatementMargins
| Gross Margin | 57.65% |
| Operating Margin | -1,848.88% |
| Pretax Margin | -2,187.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -113.52% |
| Shareholder Yield | -113.52% |
| Earnings Yield | -60.40% |
| FCF Yield | -30.81% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 16, 2024. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
Mangoceuticals has an Altman Z-Score of 0.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.67 |
| Piotroski F-Score | 2 |
